Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652Phase 2Completed
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of anastrozole, letrozole, exemestane, tamoxifen in breast cancer. Started Feb 2022; status: completed.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05150652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150652.